Ranbaxy Falls After Second Recall of Generic Lipitor in U.S.
This article is for subscribers only.
Ranbaxy Laboratories Ltd. fell the most in more than a month in Mumbai trading after a second U.S. recall of its generic version of Pfizer Inc.’s Lipitor drug.
The Indian drugmaker’s shares fell as much as 3.9 percent to 356 rupees, headed for the biggest decline since Jan. 27, before trading at 357 rupees at 9:37 a.m. local time. The benchmark S&P BSE Sensex gained 0.2 percent.